1. Introduction {#s0005}
===============

Over the past years, it has increasingly been acknowledged that the second most common neurodegenerative disorder, Parkinson\'s disease (PD), affects males and females differently ([@bb0170]; [@bb0175]). Among others, previous reports have suggested a less frequent incidence and more benign phenotype in women, which is thought to be mediated by neuroprotective effects of estrogens and genetic factors ([@bb0170]; [@bb0175]; [@bb0380]; [@bb0050]).

In the context of non-motor symptoms (NMS) in PD, impairments in facial emotion recognition have constantly been a matter of debate ([@bb0320]; [@bb0030]; [@bb0165]; [@bb0120]; [@bb0195]). Hereby, several studies reported deficits in PD patients in the recognition of fear and/or sadness ([@bb0020]; [@bb0275]; [@bb0340]), others revealed impairments in the recognition of anger and/or disgust ([@bb0275]; [@bb0065]; [@bb0240]; [@bb0375]; [@bb0060]). Adding to the inconsistency, a number of studies failed to observe any abnormalities ([@bb0010]; [@bb0305]; [@bb0200]). As shown by a previous meta-analysis on this topic, gender differences have almost fully been neglected in this context ([@bb0165]) and might be a major source for the variety of outcomes. To our knowledge, there only is one study specifically addressing the impact of gender on facial emotion recognition in a subanalysis and with a small sample of 20 PD patients (ten male; [@bb0060]). This study revealed a confined impairment of male patients at identifying fear and thus authors suggest that male patients might experience greater pathology than female patients in brain regions involved in the processing of fear (e.g. the amygdala; [@bb0060]). These assumptions remain speculative due to the lack of imaging data and thus uncertainty on the underlying neural mechanisms. However, studies that have actually focused on the neural underpinnings of impaired emotion processing in PD affirm the hypothesis of amygdala involvement (e.g., [@bb0195]; [@bb0385]; [@bb0420]). Apart from that, proposed basal ganglia-thalamo-cortical circuits hint at more widespread functional brain changes during emotion processing in PD. This includes abnormalities in the PD-associated basal ganglia (putamen, pallidum, caudate nucleus) as well as the anterior cingulate cortex, hippocampus and insula ([@bb0315]; [@bb0015]; [@bb0345]; [@bb0285]; [@bb0260]). Moreover, previous studies suggest altered neuroanatomy and functioning of other limbic structures, such as the prefrontal and orbitofrontal cortex to underlie emotion processing deficits in PD ([@bb0195]; [@bb0285]). Nevertheless, there are also studies lacking identification of any differences in neural activity between PD patients and HC for these regions (e.g., [@bb0345]). Hormonal factors such as concentration of progesterone, estradiol and testosterone have been found to mediate performance in emotion recognition and the concomitant neural response in brain regions such as the amygdala, orbito- and prefrontal cortex in general ([@bb0085]; [@bb0090]; [@bb0155]; [@bb0415]; [@bb0360]; [@bb0095]). Overall, high progesterone levels have been associated with increased amygdala reactivity and emotional memory in females ([@bb0370]). In males, endogenous testosterone levels seem to be negatively related to amygdala and positively associated with ventromedial prefrontal cortex responses to faces displaying anger ([@bb0360]). On the genetic level, serotonergic gene polymorphisms and in particular the repeat length polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) have been associated with altered brain circuit activation during emotional facial processing ([@bb0325]). Not only is this candidate gene suggested to regulate limbic activation such as amygdala response to threat-related stimuli but also to be implicated in mood disorders in PD ([@bb0290]; [@bb0280]). Additionally, the functional Val158Met polymorphism of the catechol-*O*-methyltransferase (COMT) gene determines metabolic degradation of dopamine in the prefrontal cortex via the COMT enzyme ([@bb0405]), which in turn has been reported to be a critical component for emotion recognition ([@bb0220]; [@bb0350]; [@bb0355]). In this context, the COMT Val158Met polymorphism has for instance been shown to influence limbic and prefrontal brain activation in response to emotional stimuli ([@bb0350]; [@bb0105]) and to impact gender-related activation patterns in limbic and paralimbic brain regions ([@bb0210]; [@bb0110]). Interestingly, estrogen was previously found to down-regulate COMT activity and by this to positively impact emotion processing ([@bb0210]; [@bb0070]), which may also underline the assumption of a neuroprotective effect of estrogen ([@bb0170]; [@bb0175]; [@bb0380]; [@bb0050]). Accounting for the hormonal and genetic modulation additionally to a possible gender effect will help determining individual phenotypical disease manifestations and contribute to a better understanding of the previous inconsistency in results regarding emotion processing in PD.

In view of these considerations, we aimed at (i) investigating emotion recognition deficits and their underlying neural correlates in PD patients compared to HC by applying functional magnetic resonance imaging (fMRI). Based on previous behavioural data ([@bb0060]), we expected particularly male patients to exhibit worse performance in emotion recognition and specific neural activity alterations in the named brain regions associated with PD and emotion processing (e.g. basal ganglia and insula). Concerning gender, we further intended to (ii) investigate the effects of sex-related hormones on emotion recognition and processing. Here, we especially expected estrogen and progesterone to moderate preserved emotion recognition performance in female patients and testosterone levels to modulate the respective limbic and prefrontal cortex responses in males (cf. [@bb0360]; [@bb0370]; [@bb0210]; [@bb0070]). Finally, we aimed at (iii) exploring the contribution of the genetic polymorphisms 5-HTTLPR and COMT Val158Met to emotion processing deficits in PD. Given the genetic influence of COMT Val158Met and 5-HTTLPR on emotion recognition and on activity in brain regions critical for emotional processing, we expected both polymorphisms to modulate emotion processing in PD.

2. Methods {#s0010}
==========

2.1. Participants, neurological and neuropsychological assessment {#s0015}
-----------------------------------------------------------------

Our study was conducted in accordance with the declaration of Helsinki. All participants gave written informed consent prior to participation in this study, which was approved by the institutional review board of the RWTH Aachen University (EK027/13).

51 PD patients (26 male; age: 64.0 ± 9.2 years; [Table 1](#t0005){ref-type="table"}) were recruited via the outpatient Clinic for Movement Disorders at the Department of Neurology, RWTH Aachen University, and compared to 44 age- and gender-matched HC (25 male; age: 62.9 ± 9.4 years). From this sample, 25 patients (12 male; age: 62.4 ± 10.9 years; Supplementary Table S-1) and 31 HC (17 male; age: 61.5 ± 10.2 years) showed no MR contraindications and underwent structural and functional MRI.Table 1Sample characteristics.Table 1PD patients (n = 51)HC (n = 44)PD vs. HC/♂ vs. ♀♂ (n = 26)♀ (n = 25)♂ (n = 25)♀ (n = 19)**Demographics** Age (in years)63.9 ± 8.464.0 ± 10.062.6 ± 9.063.4 ± 10.1n.s. MWT-B (IQ)116.6 ± 16.4120.0 ± 27.5118.3 ± 28.0125.0 ± 13.5n.s. MRI (n)12131714n.a.**Clinical and neuropsychological data** DD (in months)98.2 ± 81.965.9 ± 44.8n.a.n.a.n.s. UPDRS-III26.8 ± 11.620.0 ± 7.7(0.8 ± 1.1)(0.8 ± 0.9)♂ vs. ♀ PD: t = 2.43; p = 0.019 UPDRS total44.0 ± 17.233.4 ± 13.1(2.0 ± 1.9)(2.0 ± 1.8)♂ vs. ♀ PD: t = 2.46; p = 0.018 Hoehn & Yahr†2.0 \[1.5; 2.6\]1.5 \[1.0; 3.0\]n.a.n.a.n.s. LEDD578.4 ± 97.6651.1 ± 391.1n.a.n.a.n.s. DA-/non-DA recipients††20/618/7n.a.n.a.n.s. NMS-Quest10.6 ± 4.67.8 ± 4.0(2.9 ± 2.5)(2.9 ± 2.1)♂ vs. ♀ PD: t = 2.28; p = 0.027 Motor subtype: TD/AR††11/157/18n.a.n.a.n.s. Motor onset: L/R††13/1312/13n.a.n.a.n.s. BDI-II8.0 ± 4.610.4 ± 8.14.1 ± 4.23.2 ± 3.5PD vs. HC: F = 23.04; p \< 0.0001 BAI9.1 ± 6.810.8 ± 8.62.9 ± 3.92.0 ± 3.2PD vs. HC: F = 34.03; p \< 0.0001 TAS-2641.0 ± 8.341.7 ± 9.040.5 ± 8.537.0 ± 6.5n.s. MoCA28.0 ± 1.328.3 ± 1.328.2 ± 1.528.7 ± 1.5n.s. Digit span Forward8.5 ± 1.89.0 ± 2.29.0 ± 1.78.7 ± 1.9n.s. Backward6.4 ± 1.47.0 ± 1.97.1 ± 2.07.6 ± 2.3n.s. BFRT44.3 ± 3.944.4 ± 4.845.3 ± 3.645.6 ± 3.5n.s.**Hormone levels**^1^ Testosterone14.3 ± 6.10.5 ± 0.414.4 ± 4.10.3 ± 0.2n.s.^2^ Estradiol18.9 ± 10.08.9 ± 9.116.8 ± 8.75.2 ± 0.7n.s.^2^ Progesterone0.3 ± 0.20.5 ± 1.40.3 ± 0.20.1 ± 0.1n.s.^2^**Genetic polymorphisms** 5-HTTLPR low/high^††^17/918/617/715/0♂ vs. ♀ HC: p = 0.031 Val158Met COMT low/high^††^18/818/620/413/2n.s.[^2]

Participants were all Caucasian, right-handed as confirmed by a laterality quotient of ≥50 of the Edinburgh Inventory for Assessment and Analysis of Handedness ([@bb0300]), and had no history of neurological and psychiatric conditions other than PD. The latter was also confirmed by the short German version of the Structured Clinical Interview for DSM-IV (SKID-screening; [@bb0080]). All subjects were further screened for global cognition and only included if the Montreal Cognitive Assessment (MoCA; [@bb0295]) did not indicate cognitive impairment (cut-off score ≥26). As a measure of educational level premorbid intelligence was estimated using the German "Mehrfachwahl-Wortschatztest" (MWT-B; [@bb0245]), while attention and working memory were measured with the digit-span test (forward and backward) from the Wechsler Memory Scale. We further screened for depression and anxiety using the Beck Depression Inventory (BDI-II; [@bb0040]) and the Beck Anxiety Inventory (BAI; [@bb0035]) as well as for alexithymia using the 26 item version of the Toronto Alexithymia Scale (TAS-26; [@bb0230]).

Motor and non-motor functioning of PD patients and HC were examined with the Unified Parkinson\'s Disease Rating Scale (UPDRS I-IV; [@bb0140]), Hoehn and Yahr Scale (H&Y; [@bb0185]) and Non-Motor Symptoms Questionnaire (NMS-Quest; [@bb0055]). HC displaying any signs for abnormalities (e.g. UPDRS-III score \>5 not explained otherwise) were excluded from the study. In PD, we also used the UPDRS-III to calculate tremor/non-tremor scores ([@bb0250]), and classified patients as tremor dominant (scores ≥1) or akinetic-rigid (scores ≤0.8). We further interviewed patients concerning their disease history, side of motor onset and intake of dopaminergic medication (including dopamine agonists), and calculated the mean levodopa equivalent daily dose (LEDD; [@bb0390]). Female participants were further surveyed regarding hormonal factors. All of them were postmenopausal, except for three patients and two HC, additionally reporting intake of oral contraceptives.

2.2. Emotion recognition and fMRI paradigm {#s0020}
------------------------------------------

To evaluate general face perception, we performed the 16-item version of the Benton facial recognition test (BFRT; [@bb0045]). We further used the computer-based Ekman 60faces test ([@bb0130]), which provides 60 validated photographs and examines the participants\' abilities to identify emotional facial expressions including happiness, disgust, anger, fear, sadness and surprise. After being familiarized with the task by five test trials prior to the actual experiment participants were asked to name the emotion that best described the facial expression displayed on the computer screen. Stimuli disappeared after 5 s but there was no limit on response time hereafter.

Neural response to emotional facial expressions was assessed using event-related fMRI, during which subjects watched 120 videos of three seconds duration of actors performing the emotions happiness, sadness, anger, fear, disgust and neutral (20 clips each) as detailed by [@bb0100]. To ensure maintenance of attention, each video was followed by an instruction to categorize the respective emotion by choosing one of the two options provided at the bottom of the screen via key press. One of the displayed labels represented the correct option; the second one was randomly assigned. Subjects were asked to respond as quickly as possible within 3 s. Afterwards, a fixation cross (baseline) appeared with a jittered inter-stimulus interval of 12--16 s (according to [@bb0075]) with no specific task.

2.3. MRI data acquisition {#s0025}
-------------------------

MRI measurements were run on a 3 Tesla Siemens MR Scanner (Siemens Medical Systems, Erlangen, Germany). To detect specific structural alterations in PD compared to HC, we performed high-resolution T1-weighted anatomical imaging (TR = 2.3 s, TE = 2.98 ms, TI = 900 ms, FoV = 240 × 256mm, 240 × 256 matrix, 176 sagittal slices, slice thickness = 1 mm). Event-related fMRI images were acquired using gradient echo planar imaging (EPI; TR = 2.2 s, TE = 30 ms, FoV = 198 × 198mm, 64 × 64 matrix, 36 slices, slice thickness = 3 mm), starting with five dummy images allowing for MR signal saturation.

2.4. Analysis of functional imaging data {#s0030}
----------------------------------------

Processing and statistical analysis of fMRI data were performed using SPM 8 ([www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm){#ir0005}) running on Matlab 7.2 (Mathworks Inc., Sherborn, MA, USA). We first performed slice scan time correction to control for artefacts resulting from non-simultaneous slice acquisition. Functional images were then realigned to mean EPI volumes, co-registered with subject-specific anatomical images, normalized and smoothed with an 8 mm full-width-at-half maximum (FWHM) isotropic Gaussian kernel as detailed elsewhere ([@bb0100]). PD patients and HC did not show major head movements of \>4 mm and \>3°. We analysed data by a two-level approach applying the general linear model (GLM; [@bb0145]). For single subject analyses, we convolved the hemodynamic response with the onset of each experimental event, while accounting for motion artefacts using the realignment parameters as nuisance covariates. We created contrast images for every subject by comparing each facial expression with the implicit baseline. The second-level model was generated using a full factorial design for each emotion, where we tested activation differences between groups (male PD versus male HC, female PD versus female HC) using age as a covariate. We conducted whole brain analyses using cluster-level family-wise error (FWE) correction at p ≤ 0.05 (uncorrected at voxel-level with p ≤ 0.001) and labeled brain structures using the Anatomy Toolbox version 2.2c ([@bb0125]). In addition, we specified PD- and emotion-related regions of interest (ROI) based on the literature on emotion processing in PD and functional imaging studies in HC ([@bb0345]; [@bb0150]; [@bb0005]; [@bb0310]). Accordingly, our a priori ROI comprised the amygdala, insula, anterior cingulate cortex, (para-) hippocampal gyri, orbitofrontal and medial prefrontal cortices, pallidum, caudate nucleus and putamen. We also considered the thalamus as a ROI as it is strongly interconnected with the basal ganglia which are known to play a key role in PD pathology ([@bb0330]). As detailed elsewhere ([@bb0100]), pre-defined ROI masks were unilaterally derived by means of cytoarchitectonic probabilistic maps from the Anatomy-Toolbox ([@bb0125]) or the Automatic Anatomical Labeling atlas implemented in the WFU Pickatlas ([@bb0395]; [@bb0270]; [@bb0265]). ROI results were thresholded at p ≤ 0.05 using FWE-correction at voxel-level and an extend threshold of k ≥ expected voxels (8 mm^3^ voxel size) per cluster implemented in SPM.

To systematically investigate the association of clinical and endocrinal parameters with neural activity during emotion processing, we extracted functional parameter estimates for each of the significant ROIs and ran exploratory post-hoc analyses. However, on the genetic level, MRI subgroups of the COMT and 5-HTTLPR genes were too small to carry out statistical analyses.

2.5. Voxel-based morphometry analysis {#s0035}
-------------------------------------

We applied voxel-based morphometry (VBM; [@bb0025]; [@bb0160]) using the VBM8 toolbox (<http://dbm.neuro.uni-jena.de/vbm>) to compare regional gray matter (GM) differences between patients and HC. Data preprocessing was performed following the standard VBM8 pipeline and was previously described elsewhere ([@bb0100]). After non-linear modulation of normalized GM images to correct for individual brain sizes and smoothing with an 8 mm FWHM Gaussian kernel, we again employed a full factorial design including the factors group and gender and tested for GM differences between groups (male PD versus male HC, female PD versus female HC) with age as nuisance variable. Results were thresholded at p ≤ 0.05 using FWE-correction at the voxel-level (1.5 mm isotropic) across the whole brain and within the same ROI used in fMRI analyses.

2.6. Genetic and endocrinal testing {#s0040}
-----------------------------------

Blood samples were analysed concerning levels of plasma testosterone, 17β-estradiol (estrogen) and progesterone and genotyped for 5-HTTLPR and Val158Met COMT polymorphisms in the Laboratory Diagnostics Centre and Institute of Human Genetics of the RWTH Aachen University. We based statistical analyses of the 5-HTTLPR polymorphism on the tri-allelic dichotomized classification model ([@bb0225]). Accordingly, we considered 5-HTTLPR genotypes (short \[S\]/long \[L\] alleles) and supplementary effects of the single nucleotide A/G-polymorphism (rs25531) and distinguished low-functioning SS, SLG, LGLG, SLA and LALG from high-functioning LALA variants. Participants were further genotyped and grouped according to Val158Met COMT polymorphisms into high-functioning valine (Val/Val) and low-functioning methionine carriers (Met/Met and Val/Met).

2.7. Statistical analyses of behavioural data {#s0045}
---------------------------------------------

We analysed our data using the software application IBM SPSS Statistics 21 (Armonk, NY, USA). Group and gender differences in clinical, neuropsychological test scores and hormone levels were tested using two-sample *t*-tests, analyses of variances or Mann-Whitney-*U* tests where appropriate.

Emotion recognition was studied for each condition by means of analyses of covariances (ANCOVA) with the factors group (PD/HC) and gender (male/female) including age as covariate. Further, ANCOVA with the factors group (PD/HC) and genetic expression (5-HTTLPR/Val158Met COMT) were applied to analyse the impact of the dichotomous genetic variables. However, due to the less frequent gene expression of 5-HTTLPR-LALA and Val158Met COMT Val/Val gene variants in female HC (cf. [Table 1](#t0005){ref-type="table"}), ANCOVA including the factor gender were only carried out for patients. To further assess the association of emotion recognition and processing with clinical (e.g. disease duration, UPDRS-III) and hormonal data (testosterone, estradiol, progesterone), we performed correlation analysis using Spearman\'s rho or Pearson\'s product-moment coefficients where appropriate. For all analyses, we set a p-value of ≤0.05 as threshold for statistical significance, Bonferroni-corrected for the number of emotions.

3. Results {#s0050}
==========

3.1. Sample characteristics {#s0055}
---------------------------

Detailed characteristics of the study sample are summarized in [Table 1](#t0005){ref-type="table"}. Additionally, MRI subsample data are presented in Supplementary Table S-1 and a detailed comparison of the MRI subsample with the sample exclusively undergoing behavioural examination in Supplementary Table S-2. There were no group or gender effects regarding age, global cognitive abilities (MoCA), premorbid intelligence (MWT-B), attention and WM (digit-span test) as well as alexithymia (TAS-26). However, we found significantly greater anxiety (PD: 10.0 ± 7.7; HC: 2.5 ± 3.6; F1,88 = 32.7, p \< 0.0001) and more depressive symptoms (PD: 9.2 ± 6.7; HC: 3.7 ± 3.9; F1,88 = 22.9, p \< 0.0001) in patients compared to HC, but no main or interaction effects with gender. In PD, there were no gender differences regarding H&Y scores (p = 0.275), disease duration (t49 = 1.74; p = 0.089) or LEDD (t49 = 0.66; p = 0.514), but males presented with higher NMS-Quest, UPDRS-III and UPDRS total scores than females ([Table 1](#t0005){ref-type="table"}).

3.2. Emotion recognition {#s0060}
------------------------

All participants exhibited normal face processing according to BFRT-scores (PD: 44.4 ± 4.3; HC: 45.4 ± 3.6; t~92~ = 1.3, p = 0.206) and showed above chance accuracy in overall emotion recognition (Ekman 60faces test; PD: 55%--93%; HC: 53--92%; chance: 16.7%).

With regard to potential differences between groups, we found a main effect of gender with females outperforming males in total emotion recognition performance (F~1,90~ = 6.20; p = 0.015; [Table 2](#t0010){ref-type="table"}). Analysis of specific emotions showed that this gender effect also emerged for the recognition of disgust (F~1,90~ = 8.37; p = 0.030, Bonferroni-corrected; [Table 2](#t0010){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}). We further identified a significant interaction of group and gender for the recognition of anger (F~1,90~ = 7.76; p = 0.042; Bonferroni-corrected). Post-hoc *t*-tests showed no significant differences in females (PD versus HC) and between female and male HC, while male PD patients performed significantly worse than female PD patients (t~49~ = 2.62; p = 0.012) and male HC (t~49~ = 2.41; p = 0.020; [Table 2](#t0010){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}). Results withstood the correction for the PD-related variables displaying significant differences between male and female patients (i.e., NMS-Quest, UPDRS-III and UPDRS total score) as well as the correction for disease duration. Apart from that, there were no significant effects for dopamine agonist intake.Fig. 1Significant group differences in emotion recognition according to the Ekman 60 faces test.Note: PD = Parkinson\'s disease; HC = healthy controls; data represent means (95% confidence interval shown as error bars); ANCOVA with the factors group (PD versus HC) and gender (male versus female) revealed a significant main effect of gender for the recognition of disgust (male \< female; F~1,90~ = 8.37, p = 0.030, Bonferroni-corrected) and a significant interaction between group and gender on the recognition of anger (F~1,90~ = 7.76, p = 0.042, Bonferroni-corrected) with male PD \< female PD (t~49~ = 2.62, p = 0.012) and male PD \< male HC (t~49~ = 2.41, p = 0.020).Fig. 1Table 2Emotion recognition according to the Ekman 60faces test.Table 2PD PatientsHealthy ControlsANOVA (p-values)MaleFemaleMaleFemaleMain effectsInteractionGroupGenderGroup by genderAnger73.1 ± 20.086.0 ± 14.784.4 ± 12.676.8 ± 22.91.01.0**0.042**Fear55.0 ± 24.057.6 ± 25.550.0 ± 24.058.4 ± 25.01.01.01.0Happiness98.0 ± 4.999.2 ± 2.898.4 ± 3.799.0 ± 3.21.01.01.0Sadness73.1 ± 20.074.8 ± 16.973.2 ± 17.375.3 ± 19.81.01.01.0Disgust68.1 ± 21.072.4 ± 22.264.0 ± 24.385.3 ± 15.41.0**0.030**0.354Surprise86.9 ± 11.992.0 ± 11.581.2 ± 14.286.3 ± 12.60.2040.3361.0Total75.7 ± 9.080.3 ± 8.875.2 ± 8.780.1 ± 11.20.799**0.015**0.928[^3]

3.3. Structural and functional MRI {#s0065}
----------------------------------

Whole brain VBM analyses did not reveal significant differences between patients and HC. However, ROI analyses unveiled bilateral GM atrophy in female patients relative to female HC in the putamen (left cluster maxima \[MNI-coordinates x/y/z\]: −32/−1/1, t = 3.85, k~E~ = 188vox, p = 0.018; right: 30/−4/−9, t = 4.00, k~E~ = 158vox, p = 0.012).

For the fMRI task, there were no significant group differences in emotion recognition performance behaviourally (emotion recognition: all p ≥ 0.066, reaction times: all p ≥ 0.096; Bonferroni-corrected for the number of emotions). Both whole brain and ROI analyses did not reveal significant differences in blood‑oxygen-level dependent (BOLD) response between PD patients and HC or between female patients and female HC. However, male patients compared to male HC presented decreased neural activity during videos displaying angry, happy, sad and neutral faces. More precisely, male PD patients displayed decreased activity in the bilateral insula extending to the putamen, left thalamus, Heschl\'s gyrus and right superior temporal gyrus while processing angry facial expressions ([Table 3](#t0015){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}). During processing of happy faces, male patients further showed decreased BOLD-response in the left thalamus extending to the left putamen and Heschl\'s gyrus as well as in the right middle and inferior temporal gyrus, while processing of sad faces revealed decreased activity of the bilateral insula, putamen, hippocampus, fusiform gyrus and cerebellum (lobule V), left thalamus and Heschl\'s gyrus, and right superior and inferior temporal gyrus. For this emotion ROI analyses additionally unveiled decreased activity of the right parahippocampus. Furthermore, ROI analyses showed decreased activity during the processing of neutral facial expressions ([Table 4](#t0020){ref-type="table"}). Of note, the above stated results withstood the correction for premorbid intelligence (MWT-B scores), which was reduced in both female and male PD patients undergoing MRI as compared to the subsample exclusively being assessed behaviourally (cf. Supplementary Table S-2). Apart from that, results remained unchanged when controlling for disease duration and there were no significant effects for dopamine agonist intake.Fig. 2Significant group differences in neural response during emotion processing.Note: PD = Parkinson\'s disease; HC = healthy controls; L:R = left:right; coordinates in MNI space; colour bars represent T-values; A) Significant differences between male PD patients and male HC in neural response during emotion processing; results are cluster-level FWE-corrected at p ≤ 0.05 (uncorrected at the voxel level with p ≤ 0.001) across the whole brain. B) Parameter estimates showing group differences in selected regions of interest (ROI); results are FWE-corrected at p ≤ 0.05 within ROI (MNI coordinates in brackets); data represent means (95% confidence interval shown as error bars).Fig. 2Table 3Significant group differences in neural response revealed by whole brain analysis of emotion processing.Table 3Anatomical regionMNI co-ordinatesL/RxyzT**Sadness: Male HC \> Male PD**InsulaL−34−1824.08R38−8−43.86PutamenL−30−1064.07R321044.15ThalamusL−6−2685.05HippocampusL−16−3484.57R36−30−104.43Fusiform GyrusL−18−36−164.46R28−40−104.35Cerebellum (lobule V)L−4−58−64.33R20−42−223.87Heschl\'s GyrusL−40−1844.03Superior Temporal GyrusR46−12−84.38Inferior Temporal GyrusR40−58−83.95  **Anger: Male HC \> Male PD**InsulaL−3012−124.49R341444.52PutamenL−28−8124.24R3214−44.20ThalamusL−22−12124.50Heschl\'s GyrusL−38−2044.30Superior Temporal GyrusR44−8−64.88  **Happiness: Male HC \> Male PD**PutamenL−32−10−24.54ThalamusL−20−6104.71Heschl\'s GyrusL−40−2023.96Middle Temporal GyrusR48−5464.36Inferior Temporal GyrusR42−56−63.84[^4]Table 4Significant group differences in neural response during emotion processing in a priori defined regions of interest (ROI).Table 4Anatomic regionMNI co-ordinatesAnatomic regionMNI co-ordinateskxyzTkxyzT**Anger: Male HC \> Male PDSadness: Male HC \> Male PD**PutamenL180−24−12104.46PutamenL94−180104.83R57321244.48R61321044.005332−863.98ThalamusL87−22−12124.50ThalamusL123−6−2685.0578−14−4104.98InsulaL64−2814104.52InsulaR35361243.9634−3012−124.49R104341444.52HippocampusR8736−30−104.438342−8−44.84ParahippocampusR5728−38−84.34  **Neutral: Male HC \> Male PDHappiness: Male HC \> Male PD**PutamenR5628884.22PutamenL265−22−8104.58ThalamusL97−8−2885.47[^5]

3.4. Association of emotion recognition with clinical, hormonal and genetic variables {#s0070}
-------------------------------------------------------------------------------------

There were no correlations between emotion recognition performance and disease duration, LEDD, NMS, UPDRS-III, H&Y or tremor/non-tremor scores in PD patients. Neither patients nor HC displayed correlations between emotion recognition and BAI or BDI-II scores.

Estradiol, progesterone and testosterone levels of female and male patients did not differ from those of HC, respectively (cf. [Table 1](#t0005){ref-type="table"}). Female patients displayed a positive correlation of fear recognition with estradiol levels (*r* = 0.561, p = 0.030; Bonferroni-corrected). There was no other correlation of hormonal levels and emotion recognition.

Distribution of 5-HTTLPR and Val158Met COMT genotypes did not significantly differ from expected frequencies at Hardy-Weinberg equilibrium in PD patients and HC (distribution specified in [Table 1](#t0005){ref-type="table"}). ANCOVA with the factors group and genetic expression did not show any main or interaction effects of 5-HTTLPR and Val158Met COMT. However, in patients ANCOVA with the factors gender and genetic expression revealed a significant main effect of Val158Met COMT on fear recognition (F~1,45~ = 7.70; p = 0.048; Bonferroni-corrected) but no gender effects. Accordingly, patients with Met alleles performed better than those carrying Val/Val variants ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Association of fear recognition with Val158Met COMT in PD.Note: Val158Met COMT = functional Val158Met polymorphism of the catechol-*O*-methyltransferase gene; PD = Parkinson\'s disease; data represent means (95% confidence interval shown as error bars); ANCOVA with the factors gender and Val158Met COMT expression (low functioning methionine versus high functioning valine gene variants) showed a significant main effect of Val158Met COMT on fear recognition in PD patients (F~1,45~ = 7.70, p = 0.048, Bonferroni-corrected: Val/Val \< Met/Met & Val/Met).Fig. 3

3.5. Association of fMRI data with clinical and hormonal variables {#s0075}
------------------------------------------------------------------

Neither in HC nor in PD did we find significant correlations of neural activity with BAI or BDI-II scores as well as any PD-related variables (i.e., disease duration, LEDD, NMS-Quest, UPDRS-III, H&Y or tremor/non-tremor scores). Apart from that, neural activity did not correlate with emotion recognition performance in the Ekman 60faces test. During the processing of sad faces, female HC displayed a trend for a negative correlation of estradiol levels with activity in the right putamen (*r* = −0.681, p = 0.060; Bonferroni-corrected), while in male HC there was a trend for a positive correlation of progesterone levels with activation in the left putamen during the processing of happiness (*r* = 0.614, p = 0.054; Bonferroni-corrected). There were no correlations between neural activity and hormonal data in PD patients.

4. Discussion {#s0080}
=============

This multimodal behavioural and imaging study demonstrates gender-specific effects in emotion processing in non-demented PD patients, revealing worse recognition performance of the emotion anger accompanied by reduced neural response to emotional stimuli in male but not female patients. Sex-specific hormones such as estradiol and genetic factors (e.g., Val158Met COMT polymorphism) seem to contribute to these differences in emotion processing in PD.

4.1. Emotion recognition and gender {#s0085}
-----------------------------------

Our analyses revealed a confined impairment of male but not female PD patients in recognizing the emotion anger, which is in line with previous suggestions of female PD patients developing more benign disease phenotypes ([@bb0170]; [@bb0175]; [@bb0380]; [@bb0050]).

Similarly to our findings, the only preceding study on gender differences in emotion recognition in PD reported a confined impairment of fear recognition in male PD patients, whereas impaired recognition of anger was not related to gender ([@bb0060]). The limited sample size used in Clark et al. might at least partially provide an explanation for the divergence of findings. Also, with fear and anger being the most difficult emotions to identify ([@bb0135]), differences in cognitive states of included samples might additionally have led to inconsistent results. In the current study both female and male PD patients reached mean MoCA scores of ≥28 points (male PD patients: 28.0 ± 1.3; female PD patients: 28.3 ± 1.3), while the PD sample of Clark et al. reached a mean score of 28.7 ± 1.4 in the Mini-Mental State Examination, which roughly corresponds to a MoCA score of 25--26 points ([@bb0365]).

4.2. Neural correlates of emotion processing {#s0090}
--------------------------------------------

In addition to the impaired recognition of anger, male PD patients also showed reduced neural activity during fMRI. During the processing of angry, sad, happy and neutral faces, male PD patients mainly showed diminished activity of the putamen and thalamus. Putaminal involvement is in line with the amplified model of coexisting cortico-basal ganglia circuits, explaining the degeneration of cognitive (associative loop) and emotional-limbic functions (limbic loop; [@bb0330]; [@bb0115]) in PD. In the same vein, PD patients have been shown to exhibit decreased bilateral putaminal activation while confronted with emotionally evocative stimuli from the International Affective Picture System ([@bb0235]). Interestingly, reduced striatal dopamine transporter availability of the left putamen has previously also been found to correlate with PD patients\' errors in emotional gesture recognition ([@bb0260]). Our finding of decreased thalamic response further indicates PD-related disruptions in cortico-striatal pathways and emphasizes the role of the thalamus in emotion processing as previously shown for healthy subjects ([@bb0335]), Huntington\'s disease ([@bb0100]) and other cognitive domains in PD ([@bb0400]; [@bb0205]). During the processing of angry and sad faces, but not during emotions of positive (happiness) or neutral valence, male patients displayed diminished insula activation. This is in accordance with previous notions that the insula is a neural substrate for aversive or threat-related stimuli ([@bb0315]; [@bb0335]). Concerning the processing of fear, especially amygdala involvement has been discussed to underlie PD-related emotional dysfunctions (e.g., [@bb0195]; [@bb0060]; [@bb0385]; [@bb0420]). However, in line with previous findings suggesting diminished amygdala reactivity in PD to be compensated by dopamine replenishment ([@bb0385]), we did not identify neural activity alterations in this region. Similarly, Schienle and colleagues ([@bb0345]) do also not report decreased amygdala response for the processing of fear and discuss that prior findings of diminished neural response might result from a neglect of confounders, such as higher apathy and/or depression scores of PD patients as compared to HC (e.g., [@bb0410]).

Although not reflected in the Ekman 60faces test, sadness evoked the most widespread neural activity alterations in our male PD sample while neutral and happy facial expressions resulted in reduced neural activity as well. These findings indicate a more general impairment of male PD patients in response to facial expressions. The clear dissociation as compared to our behavioural data may result from fMRI detecting marginal alterations more sensitively. In the same vein, the dynamic emotion-expressing videos used during fMRI may have evoked stronger response than the static and possibly less realistic black and white pictures presented during the offline task. Importantly, neural correlates of dynamic facial emotion recognition have also been reported to differ from those involved in static facial emotion recognition (e.g., [@bb0215]) and methodological issues can thus not be excluded to have contributed to the above stated inconsistency. One of the key regions displaying significantly higher activation for the perception of static as compared to dynamic facial expressions seems to be the medial prefrontal cortex ([@bb0215]). This may also explain why we did not find any activity alterations in the medial prefrontal cortex, while previous studies applying static images reported altered neuroanatomy and functioning of this region to underlie emotion processing deficits in PD ([@bb0195]; [@bb0285]). Despite the alterations on the neural level, PD patients recognized the respective emotions of the fMRI task to the same level as HC. While this finding lacks correlation with Ekman 60faces performance, it may again point to the methodological issue of using static images for the offline task and videos during fMRI. We also employed a comparatively simple fMRI task during which participants solely had to choose between two provided response options in contrast to the Ekman 60faces test. Additionally, the fact that there were no differences in reaction times for the fMRI task allows the conclusion that our imaging findings are not merely explainable by processing speed deficits or cognitive dysfunction of our PD sample. Of note, the pattern of reduced activity in our male PD sample is also not merely explainable by regional brain volume loss, as VBM analysis did not indicate overt structural degeneration. In fact, we found reduced bilateral putaminal volume in female PD patients, who did not exhibit altered neural response. This again emphasizes the need to refrain from applying one standard to all PD patients but consider possibly disease-modifying variables such as gender ([@bb0170]; [@bb0175]).

4.3. Influence of hormonal and genetic variables {#s0095}
------------------------------------------------

The functional Val158Met COMT polymorphism has recently gained increasing interest with respect to emotion processing, since the COMT enzyme has been found to be involved in the metabolic degradation of the neurotransmitter dopamine in brain regions such as the prefrontal cortex, amygdala and striatum ([@bb0405]; [@bb0180]; [@bb0190]). Dopamine in these regions in turn is known to modulate brain activity to aversive stimuli and by this regulate emotion processing ([@bb0220]). The Met variant of the COMT gene is associated with lower COMT enzymatic activity as compared to the more efficient Val variant. Met thus results in slower dopamine degradation and increased synaptic dopamine in the respective neural pathways ([@bb0255]). The Val variant has consequently been associated with impaired processing of emotional stimuli, however, this effect has only been shown for emotions of negative but not positive valence ([@bb0350]; [@bb0355]; [@bb0180]). In line with this, our analyses revealed worse performance of patients with Val158Met COMT Val/Val expression compared to Met allele carriers in fear recognition. Since for the present work MRI subgroups for the COMT gene were too small to carry out statistical analyses, the underlying neural processes of this finding will have to be elucidated by future studies. Nevertheless, this finding provides evidence that genetic factors are not only to be considered when it comes to determining an individual\'s predisposition for PD but also when investigating the phenotypical manifestation of the disease. Along with that, it may provide an explanation for the bias in previous results regarding emotion and especially fear processing in PD, even though we did not discover any group (PD versus HC) or gender effects for this emotion.

Of note, estrogen has previously been shown to down-regulate COMT activity in addition to the gene variant itself ([@bb0210]; [@bb0070]). Correspondingly, we identified a positive correlation of estradiol levels with performance in fear recognition in our female PD sample, which also underlines the assumption of a neuroprotective effect of estrogen ([@bb0170]; [@bb0175]; [@bb0380]; [@bb0050]). Any interactions of COMT with estrogen as well as with dopamine replenishment resulting from dopaminergic medication may currently hamper an explanation of the exact underlying processes and future studies are needed to follow up on this complex topic.

4.4. Limitations and conclusion {#s0100}
-------------------------------

A potential limitation of our study is that we did not consider the side of motor symptom onset as a possible moderator variable, while it has previously been shown to influence emotion recognition in PD ([@bb0060]). This might also be of importance in the context of the respective neural correlates underlying emotion recognition deficits. However, side of motor symptom onset was balanced in our subjects and further subgrouping for laterality would require a larger sample. Likewise, and for the same reason, we did not study emotion processing in different PD phenotypes (tremor dominant/akinetic-rigid). Notably, post-hoc correlation analyses between tremor/non-tremor scores and performance in emotion recognition or neural activity did not indicate any coherence. However, a recent resting-state fMRI study showed that akinetic-rigid PD patients predominantly exhibit altered mesolimbic activity, while tremor-dominant patients rather present cerebellar activity alterations ([@bb0425]). Thus, diminished cerebellar activity in our male patients during the processing of sad faces might be driven by the tremor-dominant subgroup. Future studies are needed to investigate such associations.

Another limitation of our study is that disease duration was highly variable in our PD sample. However, we did not find any significant associations between disease duration and emotion processing, neither behaviourally nor with functional imaging data.

Finally, one major limitation of our study is that we employed static images during the behavioural task while using dynamic stimuli to assess the neural correlates of emotion processing in PD. As stated above (cf. 4.2 Neural correlates of emotion processing), neural correlates of static and dynamic facial emotion recognition have been reported to differ in meaningful ways (e.g., [@bb0215]) and our results should thus be interpreted carefully. Future studies should address this issue by using either static or dynamic stimuli for both conditions. On the other hand, imaging examinations studying emotion processing based on different modalities impacting the neural correlates in PD may offer new insights and strengthen converging results on emotion processing deficits in PD.

Overall, this work is the first fMRI study examining the impact of gender on emotion recognition in PD patients, providing an enhanced insight into the underlying neural mechanisms while additionally considering the influence of sex-related hormones and genetics. Our study highlights that we need to be aware of such possibly disease-modifying variables in PD, and further research on the underlying neural, endocrinological and genetic mechanisms of specific symptoms in PD is of clinical relevance, as it can improve our understanding of the phenomenology of the disease and may allow a more personalized medicine.
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[^2]: Note: PD = Parkinson\'s disease; HC = healthy controls; MWT-B = German Mehrfachwahlwortschatz-Intelligenztest Version B; MRI = magnetic resonance imaging; DD = disease duration; UPDRS = Unified Parkinson\'s disease rating scale; UPDRS-III = motor scale of the UPDRS; LEDD = levodopa equivalent daily dose; DA = dopamine agonist; NMS-Quest = non-motor symptoms questionnaire; TD/AR = tremor dominant/akinetic-rigid; L/R = left/right; BDI-II = Beck depression inventory version II; BAI = Beck anxiety inventory; TAS-26 = 26 item version of the Toronto Alexithymia Scale; MoCA = Montreal cognitive assessment; BFRT = Benton facial recognition test; 5-HTTLPR polymorphism: low functioning (SS, SL~G~, L~G~L~G~, SL~A~ & L~A~L~G~) versus high-functioning (L~A~L~A~) gene variants; Val158Met COMT polymorphism: low functioning methionine versus high functioning valine gene variants (Met/Met & Val/Met versus Val/Val); if not stated otherwise numbers indicate mean ± standard deviation (p revealed by ANOVA or two-sample *t*-tests); numbers in brackets were not included into statistical analyses and only used to rule out possible exclusion criteria in healthy controls; ^†^numbers are median and interquartile range (p revealed by non-parametric Mann-Whitney-*U* test); ^††^numbers are frequencies (p revealed by Fisher\'s exact test); ^1^women were postmenopausal, except for three patients and two HC, additionally reporting intake of oral contraceptives; PD patients and HC did not undergo hormonal replacement therapies; ^2^gender effects for hormone levels were neglected and two-sample *t*-tests were only calculated for PD vs. HC; vs. = versus; n.a. = not applicable; n.s. = not significant.

[^3]: Note: PD = Parkinson\'s disease; numbers indicate mean ± standard deviation; ANCOVA with the factors group (PD versus healthy controls) and gender (male versus female) and age as covariate; p-values are Bonferroni-corrected for the number of emotions; bold numbers indicate significant differences.

[^4]: Note: PD = Parkinson\'s disease; HC = healthy controls; L = left; R = right; T = maximum t-value for the anatomical area. Results are cluster-level family-wise error (FWE) corrected at p ≤ 0.05 (uncorrected at the voxel level with p ≤ 0.001) across the whole brain.

[^5]: Note: PD = Parkinson\'s disease; HC = healthy controls; L = left; R = right; k = number of voxels (voxel size 8 mm^3^); T = maximum t-value for the anatomical area. Results are FWE-corrected at p ≤ 0.05 within ROI.
